• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

BioMarin Surging Beneath the Surface

The pharmaceutical stock is about to go from sideways to up.
By BRUCE KAMICH
Nov 29, 2016 | 11:58 AM EST
Stocks quotes in this article: BMRN

BioMarin Pharmaceutical (BMRN) has been trading sideways for the past year, but beneath the surface accumulation has been under way. It will only take some modest improvement in our indicators to tell us the trend is about to change to up from sideways.

In this 12-month daily chart of BMRN, above, we see the overall trend is neutral, but don't stop there. Notice the pattern of higher lows from February to June and then early November? Now look at how the 200-day moving average line has behaved. In September through November, the 200-day average has changed from down to sideways to turning up. The On-Balance-Volume (OBV) line makes a low in February and then rises until mid-September. A move of the OBV to a new high as BMRN rallies over $102 will turn the chart bullish again.

In this weekly chart, above, we can see BMRN made a serious correction last year, falling from over $150 to nearly $60. The weekly OBV line is telling us a very bullish story. The price of BMRN and the OBV line rise together in 2014 and then levels off. BMRN makes that $90 decline and the OBV line only dips in November, December and January. The OBV line turns up promptly and confirms the price strength we see on this chart. A weekly close above $100 is bullish and could be the start of a rally to the $130 level.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Investing | U.S. Equity | Healthcare

More from Healthcare

A Subscriber Asks About 2 Biotech ETFs and Here's What We Found

Bruce Kamich
Apr 14, 2021 1:05 PM EDT

Traders and investors could go long IBB or XBI at current levels and look to add on strength.

Jim Cramer: Johnson & Johnson? Moderna and Pfizer Can Do the Job

Jim Cramer
Apr 13, 2021 2:35 PM EDT

You never want to be caught in a counter trend rally.

Charting NovoCure's Meteoric Stock Price Rise

Bruce Kamich
Apr 13, 2021 11:05 AM EDT

NVCR gapped sharply higher today, in one of the most impressive upside gaps we have seen in a long time. Check it out.

I'm Not Bailing on Johnson & Johnson Now

Stephen Guilfoyle
Apr 13, 2021 10:47 AM EDT

Don't forget, this is a very large company with a lot more than the vaccine going on.

Is This the Bottom of the 'Well'?

Timothy Collins
Apr 12, 2021 2:58 PM EDT

Let's check American Well Corp after it got destroyed in this tough market.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 02:42 PM EDT PAUL PRICE

    Wednesday on Real Money Pro

    Make this stock a 'part' of your portfolio.
  • 04:44 PM EDT PAUL PRICE

    Pretty Incredible + Hard to Believe

  • 11:18 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The 5 Pillars of Exceptional Trading
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login